SCHEMBL6718595

SCHEMBL6718595

O=S(=O)(c1ccccc1)N(c1cccc(C2=NCCc3ccc(F)cc32)c1)S(=O)(=O)c1cccs1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.36
TSHR P16473 1/20 0.36
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
NLRP3 Q96P20 1/20 0.33
NR3C1 P04150 1/20 0.33
MAPT P10636 1/20 0.32
TAS2R14 Q9NYV8 1/20 0.32
PKM P14618 1/20 0.31
ALDH1A1 P00352 1/20 0.31
PSEN1 P49768 1/20 0.31
PSEN2 P49810 1/20 0.31
APH1B Q8WW43 1/20 0.31
NCSTN Q92542 1/20 0.31
APH1A Q96BI3 1/20 0.31
PSENEN Q9NZ42 1/20 0.31
OXTR P30559 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718758 0.91 TSHR (0.37) MAPK10TSHRKMT2ANLRP3NR3C1
SCHEMBL6714930 0.89 MAPK10 (0.38) MAPK10MEN1KMT2ANLRP3NR3C1
SCHEMBL6718262 0.84 MAPK10 (0.39) MAPK10MEN1KMT2ANR3C1PKM
SCHEMBL6715043 0.79 CA1 (0.37) MAPK10KMT2ANLRP3NR3C1ALDH1A1
SCHEMBL7174896 0.74 CA1 (0.39) MAPK10MEN1KMT2A
SCHEMBL6718022 0.73 CA1 (0.41) MAPK10PKMALDH1A1
SCHEMBL2334077 0.72 MAPK10 (0.51) MAPK10ALDH1A1
SCHEMBL6718596 0.71 MEN1 (0.39) MAPK10MEN1KMT2AMAPTALDH1A1
SCHEMBL6718603 0.70 LMNA (0.36) MAPK10MEN1KMT2AMAPTALDH1A1
SCHEMBL6718763 0.69 MAPT (0.39) MAPK10MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A MAPK10 1836/4885TSHR 3790/4885MEN1 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.